naloxone hydrochloride · Kaleo Inc · NDA 209862

Evzio (Autoinjector)

Earliest generic entry, as listed
20 Mar 2035

No marketed reference-listed strength; date taken from all listed strengths.

Blocked by patent: US 10220158.

Listed patents · 17 unexpired

PatentClaimsExpires
US 10220158drug product, use U-2500 · sets the listed date20 Mar 2035
US 9517307drug product, use U-192518 Jul 2034
US 8627816drug product4 Feb 2032
US 10143792use U-247624 May 2031
US 10322239use U-190728 Feb 2031
US 8939943drug product28 Feb 2031
US 9022022drug product28 Feb 2031
US 9474869drug product, use U-190728 Feb 2031
US 8021344drug product2 Nov 2029
US 8226610drug product10 Apr 2029
US 8231573drug product25 Nov 2028
US 7749194drug product30 Oct 2028
US 7947017drug product12 Mar 2028
US 9724471drug product, use U-209223 May 2027
US 8206360drug product27 Feb 2027
US 9238108drug product20 Feb 2027
US 11590286drug product12 Dec 2026

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
209862 · 001 · RLD · discontinuedsolution, intramuscular, subcutaneous2MG/0.4ML (2MG/0.4ML)20 Mar 2035
Expired or delisted (4)
  • US 10960155 · product · 25 Jun 2026
  • US 7731686 · product · 1 Jun 2026
  • US 8926594 · product · 31 Mar 2026
  • US 9278182 · product · 1 Feb 2026